Licensed Rights and Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2024

Licensed Rights and Other Intangible Assets [Abstract]

Schedule of License Rights and Other Intangible Assets, Net

The following provides information about our license rights and other intangible assets, net as of June 30, 2024 and December 31, 2023 (in thousands):

	June 30, 2024						December 31, 2023
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Intangible assets subject to amortization:
Hormone therapy drug patents	$	5,753	$	1,862	$	3,891	$	6,818	$	1,871	$	4,947
Hormone therapy drug patents applied and pending approval		324		—		324		842		—		842
Intangible assets subject to amortization		6,077		1,862		4,215		7,660		1,871		5,789
Intangible assets not subject to amortization:
Trademarks/trade name rights		309		—		309		309		—		309
License rights and other intangible assets, net	$	6,386	$	1,862	$	4,524	$	7,969	$	1,871	$	6,098

Schedule of Intangible Assets Subject to Amortization

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

Year ending December 31,
2024	$	192
2025		384
2026		384
2027		384
2028		384
Thereafter		2,163
Total	$	3,891